Why the study?
The study was conducted to estimate current use of secondary prevention drugs and identify associated individual characteristics among individuals with established CVD in Chinese communities.
What is the current use of secondary prevention drugs and its associated individual characteristics among those with established cardiovascular diseases in China?
Population
2 613 035 participants aged 35-75 years across 8577 communities in 31 provinces in China
Comparison
Individual characteristics associated with reported secondary prevention drug use
Design
Community-based cross-sectional study
Authors
Loading...
Secondary prevention drug use varies by characteristics in Chinese adults with CVD; leaves open targeted strategies to improve uptake.
What is the current use of secondary prevention drugs and its associated individual characteristics among those with established cardiovascular diseases in China?
The use of secondary prevention drugs (antiplatelets and statins) among Chinese adults with established cardiovascular disease is suboptimal at 34.2%, highlighting a significant gap in care.
Lu et al. (2020) studied this question.